James V. Caruso, Chief Executive Officer at Cellectar Biosciences, Inc. (CLRB), bought 8,680 shares at $2.88 ($25K) on 2026-05-07, disclosed to the SEC on 2026-05-11.
CEO James Caruso purchased 8,680 shares at $2.88 on May 7, 2026, marking the largest insider purchase in the company's history. This bullish signal comes as the stock has rallied 16.89% over the past five days.
The stock is trading at $3.08, up 16.89% over the last five days and 9.61% over the past month, reclaiming the 52-week low of $2.45 with a 25.71% premium.
Upcoming catalysts include the Q1 2026 earnings call on May 14, 2026, which will cover clinical progress and financing; the Zacks upgrade to Buy on May 7, 2026; and the Phase 2b data showing durable responses in Waldenström Macroglobulinemia on May 5, 2026.
Recent earnings call summaries highlight 'ongoing financial hurdles' and the company's need to navigate financial challenges for future growth.
Something here stands out, but not much.
| Filing → |
| CLRB | BUY | 2020-12-28 | $50K | — | Filing → |
| CLRB | BUY | 2020-06-08 | $25K | — | Filing → |
| CLRB | BUY | 2018-11-30 | $2K | — | Filing → |